Patent ID: 6649744
Filing Date: 2003-11-18
Classification: A61K,C07K,C12N,C12Q,G01N

Abstract:
An antagonist that inhibits or an agonist that activates an activity of an RNA selected from the group consisting of: an RNA transcribed from a polynucleotide comprising an nucleotide sequence having at least a 90% identity to the amino acid sequence of SEQ ID NO:3, and an RNA transcribed from a polynucleotide comprising an nucleotide sequence set forth in SEQ ID NO:3, wherein said activity is selected from the group consisting of:Staphylococcus aureus RNaseP Km=53Â±4 nM determined in a reaction in 1Ã—buffer comprising 100 mM Tris-Cl, pH7.0, 150 mM KCl, 10 mM MgCl2, 5% PEG, and [E]=20 nM using cloned pre-tRNAphe as a substrate; Staphylococcus aureus RNaseP kcat=3.4Â±0.1 minâˆ’1 determined in a reaction in 1Ã—buffer comprising 100 mM Tris-Cl, pH7.0, 150 mM KCl, 10 mM MgCl2, 5% PEG, and [E]=20 nM using cloned pre-tRNAphe as a substrate; Staphylococcus aureus RNaseP RNA binding isotherm of Kd=8Â±1 nM for RNaseP protein determined in a reaction buffer comprising 20 mM K-Hepes, pH8.0, 0.01% NP-40, 400 mM NH4OAc, 10 mM MgCl2, and 5% glycererol; Staphylococcus aureus RNaseP V1 cleavage of nucleotides selected from the group consisting of: 8-11, 16-23, 30-33, 37-54, 64-84, 96-105, 119-130, 150-156, 166-169, 181-184, and 290-294; and Staphylococcus aureus RNase T2 cleavage of nucleotides selected from the group consisting of: 24-27, 55-60, 86-91, 106-108, 135-138, and 170-177; and said compound modulates the DEPC cleavage of nucleotides selected from the group consisting of: 159-161, A211-213.A203, 204, and A169, 292-294 (L15.2), 271 (bulged A).